AR084144A1 - Compuestos y metodos para restaurar la piel - Google Patents

Compuestos y metodos para restaurar la piel

Info

Publication number
AR084144A1
AR084144A1 ARP110104524A ARP110104524A AR084144A1 AR 084144 A1 AR084144 A1 AR 084144A1 AR P110104524 A ARP110104524 A AR P110104524A AR P110104524 A ARP110104524 A AR P110104524A AR 084144 A1 AR084144 A1 AR 084144A1
Authority
AR
Argentina
Prior art keywords
skin
alkyl
restore
compounds
methods
Prior art date
Application number
ARP110104524A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45316123&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR084144A1 publication Critical patent/AR084144A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un método para tratar una imperfección o marca de la piel, que comprende administrar una composición que comprende una cantidad terapéuticamente efectiva de un compuesto que posee la estructura de fórmula (1) en donde cada línea punteada representa la presencia o ausencia de un doble enlace; R1, R2, R3 y R4 son cada uno seleccionado independientemente entre H y alquilo lineal C1-6; R5 es halógeno, alquilo C1-6, o alquenilo C1-6; R6 es H, alquilo C1-6, alquenilo C1-6, una sal del mismo, o una amina del mismo; n es 0 - 7; y X es S ó O; en donde dicha administración trata dicha imperfección o marca de la piel.
ARP110104524A 2010-12-02 2011-12-02 Compuestos y metodos para restaurar la piel AR084144A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41911510P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
AR084144A1 true AR084144A1 (es) 2013-04-24

Family

ID=45316123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104524A AR084144A1 (es) 2010-12-02 2011-12-02 Compuestos y metodos para restaurar la piel

Country Status (16)

Country Link
US (1) US20120142684A1 (es)
EP (2) EP2646017B1 (es)
JP (1) JP2013544842A (es)
KR (1) KR20130119958A (es)
CN (1) CN103282033A (es)
AR (1) AR084144A1 (es)
AU (1) AU2011336582A1 (es)
BR (1) BR112013015781A2 (es)
CA (1) CA2819471A1 (es)
CL (1) CL2013001579A1 (es)
MX (1) MX2013006163A (es)
RU (1) RU2013129262A (es)
SG (1) SG190947A1 (es)
TW (1) TW201307313A (es)
WO (1) WO2012075174A2 (es)
ZA (1) ZA201303949B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046332A1 (en) * 2010-08-17 2012-02-23 Allergan, Inc. Compositions and methods for treating corneal haze
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US20140142042A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
CA2891595A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
CN105579438B (zh) * 2013-09-27 2019-12-06 阿勒根公司 用于皮肤修复的化合物和方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) * 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
CA2451393C (en) * 2001-07-16 2011-01-04 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
WO2003009872A1 (en) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
EP2465537B1 (en) * 2002-10-10 2016-06-29 ONO Pharmaceutical Co., Ltd. Microspheres comprising ONO-1301
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ.ホフマン−ラ ロシュ アーゲー プロスタグランジンアゴニストとしての2−ピペリドン誘導体
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2006137472A1 (ja) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. プロスタグランジン誘導体
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ep4受容体アゴニストとしてのベンズアミド誘導体
EP2120962A1 (en) * 2006-12-18 2009-11-25 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092861A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092862A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
US20110111031A1 (en) * 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
BR112013002319A2 (pt) * 2010-07-30 2016-05-24 Allergan Inc compostos e métodos para reparo da pele
EP2605762A1 (en) * 2010-08-19 2013-06-26 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition

Also Published As

Publication number Publication date
CN103282033A (zh) 2013-09-04
TW201307313A (zh) 2013-02-16
EP3195863A1 (en) 2017-07-26
BR112013015781A2 (pt) 2018-11-06
WO2012075174A2 (en) 2012-06-07
AU2011336582A1 (en) 2013-07-11
US20120142684A1 (en) 2012-06-07
CA2819471A1 (en) 2012-06-07
SG190947A1 (en) 2013-07-31
WO2012075174A3 (en) 2012-07-26
ZA201303949B (en) 2014-08-27
EP2646017A2 (en) 2013-10-09
MX2013006163A (es) 2013-10-30
KR20130119958A (ko) 2013-11-01
JP2013544842A (ja) 2013-12-19
RU2013129262A (ru) 2015-01-10
EP2646017B1 (en) 2016-11-16
CL2013001579A1 (es) 2013-12-27

Similar Documents

Publication Publication Date Title
AR084144A1 (es) Compuestos y metodos para restaurar la piel
AR082428A1 (es) Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
BR112015018284A2 (pt) amidas como moduladores de canais de sódio
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
PE20141067A1 (es) Compuestos para el tratamiento de la adiccion
BR112015018289A2 (pt) piridona amidas como moduladores de canais de sódio
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
NI201100223A (es) Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EA201792597A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
EA201391524A1 (ru) Производные гликозида и их применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure